Maritime Pine
drugOn this page
Also known as Cluster pine wholeMaritime pine wholePinus lemoniana wholePinus nigrescens wholePinus pinasterPinus pinaster barkPinus pinaster bark extractPinus pinaster wholePinus syrtica wholePycnogenol
Summary
Maritime Pine (CHEMBL2109208) is a phase-3 clinical-stage unknown; indicated across 3 conditions including attention deficit-hyperactivity disorder and varicose disease.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Unknown
- Indications: 3 conditions
- Clinical trials: 9
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2109208 |
| Name | Maritime Pine |
| Type | Unknown |
| Max phase | 3 |
Also known as: Cluster pine whole, Maritime pine, Maritime pine whole, Pinus lemoniana whole, Pinus nigrescens whole, Pinus pinaster, Pinus pinaster bark, Pinus pinaster bark extract, Pinus pinaster whole, Pinus syrtica whole, Pycnogenol, MARITIME PINE
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| attention deficit-hyperactivity disorder | 3 | MONDO:0007743 | EFO:0003888 |
| varicose disease | 2 | MONDO:0008638 | HP:0002619 |
| lymphedema | 2 | MONDO:0019297 | MONDO:0019297 |
Clinical trials
Total trials: 9.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 4 |
| Not specified | 4 |
| PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02700685 | PHASE3 | COMPLETED | Effect of Pycnogenol® on ADHD |
| NCT00064857 | PHASE2 | COMPLETED | Pycnogenol for the Treatment of Lymphedema of the Arm in Breast Cancer Survivors |
| NCT00214032 | PHASE2 | COMPLETED | Pycnogenol for the Treatment of Lymphedema |
| NCT00952627 | PHASE2 | TERMINATED | Effects of Pycnogenol on Cardiac Fibrosis and Diastolic Dysfunction in Aged Hypertensive Subjects |
| NCT04203043 | PHASE2 | UNKNOWN | The Prevstain Trial |
| NCT07266571 | Not specified | NOT_YET_RECRUITING | Pycnogenol (French Maritime Pine Bark) for the Treatment of Gulf War Illness |
| NCT00641758 | Not specified | COMPLETED | Pycnogenol and Endothelial Function in Coronary Artery Disease |
| NCT02909686 | Not specified | COMPLETED | Effects of Botanical Microglia Modulators in Gulf War Illness |
| NCT05786820 | Not specified | COMPLETED | Impact of Pycnogenol® on Gingival Inflammation |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: attention deficit-hyperactivity disorder